Christine Arnold
Managing Director
(646) 562-1322
christine.arnold@cowen.com
Christine Arnold is a managing director and senior research analyst covering the health care services sector. Prior to joining Cowen and Company in January 2009, Ms. Arnold spent more than eight years at Morgan Stanley, where she covered health care services stocks. Prior to that, she was a coverage analyst at UBS and Goldman Sachs. Ms. Arnold has ranked highly in a variety of polls, including Greenwich and Forbes. She holds a BA in business and finance from Georgetown University.
Ken Cacciatore
Managing Director
(646) 562-1305
ken.cacciatore@cowen.com
Ken Cacciatore is a managing director and senior research analyst. Mr. Cacciatore joined the Cowen and Company pharmaceutical research team in June 2000. Previously, Mr. Cacciatore worked in Cowen's health care investment banking department. He graduated from Lafayette College with a degree in economics and received an MBA from the Anderson School at UCLA.
Joshua Jennings
Director
(646) 562-1333
josh.jennings@cowen.com
Josh Jennings is a director and senior research analyst covering the medical device sector. Prior to joining Cowen and Company, Dr. Jennings was a senior vice president at Jefferies & Company, where his coverage universe consisted of large-, mid-, and small-cap medical device companies. Dr. Jennings received a BA in biology from Yale University and an M.D. from Temple University School of Medicine. He then completed the Harvard Combined Internal Medicine & Pediatrics residency before practicing as an attending physician at Massachusetts General Hospital.
Phil Nadeau
Managing Director
(646) 562-1336
phil.nadeau@cowen.com
Philip Nadeau is a managing director and senior research analyst on the biotechnology team at Cowen and Company. He has been at Cowen for 10 years and is responsible for covering 20 large-, mid-, and small-cap biotechnology stocks. He has been recognized in The Wall Street Journal's "Best on the Street" rankings, and his views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg, and the Dow Jones newswires. Prior to joining Cowen, he was a research assistant at Children's Hospital, Boston. Mr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in neurobiology from Harvard University.
Edward Nash
Managing Director
(646) 562-1385
edward.nash@cowen.com
Edward Nash is a managing director and member of the biotechnology equity research team. He joined the firm in March 2011. He had most recently been a senior research analyst at ROTH Capital Partners. Mr. Nash was with Stifel Nicolaus & Co. (formerly Legg Mason) for five years as a principal covering the biotechnology sector. Earlier in his career, Mr. Nash was associated with Ladenburg Thalmann & Co., Commerce Capital Markets, Inc. as well as Lazard Freres, LLC in their equity research departments, also focusing on biotechnology. Mr. Nash began his Wall Street career as a health care analyst at SG Cowen Asset Management, Inc. Mr. Nash graduated from Spring Hill College with a BS in biology and chemistry. He also holds an MPH degree in epidemiology from The University of Alabama at Birmingham. Mr. Nash earned both an MBA in finance and an MS in international business from The University of Miami.
Anant Padmanabhan
Vice President
(646) 562-1374
anant.padmanabhan@cowen.com
Anant Padmanabhan is a research analyst covering generic and specialty pharmaceutical companies in the U.S. and emerging markets. Mr. Padmanabhan previously worked in Washington, D.C. at FDC Reports as a reporter covering developments pertaining to health care on Capitol Hill, the FDA, and other federal agencies. Mr. Padmanabhan has a BA in mathematics from the College of Wooster, a masters in international affairs from Columbia, and an MBA from The Wharton School. He is a CFA charterholder.
Charles Rhyee
Managing Director
(646) 562-1376
charles.rhyee@cowen.com
Charles Rhyee is a managing director and senior research analyst covering the health care technology and distribution space. Mr. Rhyee has been recognized in polls conducted by The Wall Street Journal and The Financial Times. In 2008 and 2009, Institutional Investor named Mr. Rhyee "Best Up & Coming Analyst" in the health care technology & distribution space. Prior to joining Cowen and Company in February 2011, he was an executive director covering the health care technology and distribution sector for Oppenheimer & Co. Mr. Rhyee began his equity research career at Salomon Smith Barney in 1999. He holds a BA in economics from Columbia University.
Shaun Rodriguez
Vice President
(617) 946-3929
shaun.rodriquez@cowen.com
Shaun Rodriguez is a research analyst covering life science tools and diagnostics companies. Prior to re-joining Cowen in 2011, Mr. Rodriguez was a senior investment associate at the Partners Innovation Fund, the venture capital arm of Partners HealthCare, where he evaluated and executed on early stage investments across the health care sector. While at Partners, he was also a member of the business development group, where he focused on strategic initiatives in diagnostics and clinical genomics. He holds degrees from Tufts University and the University of Maine and has a Ph.D. in biological sciences from Harvard University.
Steve Scala
Managing Director
(617) 946-3923
steve.scala@cowen.com
Steve Scala is a senior research analyst with more than 15 years of experience following the pharmaceutical industry, including large-, mid- and small-cap companies. He has been a runner-up numerous times in the major pharmaceuticals category in the Institutional Investor survey. Prior to joining Cowen and Company, Mr. Scala was a pharmacist at New England Medical Center in Boston. He received a BS in pharmacy from the University of Connecticut, an MS in pharmacy from Ohio State University, and an MBA from Bentley College. He is a CFA charterholder.
Doug Schenkel
Managing Director
(617) 946-3918
doug.schenkel@cowen.com
Doug Schenkel is a managing director and senior research analyst in the medical technology research group, specializing in the life science tools, diagnostics, medical equipment, and labs industries. Prior to joining Cowen and Company's medical supplies and devices team in 2005, Mr. Schenkel was a vice president with Global Biomedical Partners, managing a life science cross-over fund. Mr. Schenkel previously worked in private equity with Triumph Capital Group and started his career with Cowen and Company in the health care investment banking group. He has a BS in business administration from Georgetown University and an MBA from the UCLA Anderson School of Business.
Eric Schmidt
Managing Director
(646) 562-1345
eric.schmidt@cowen.com
Eric Schmidt is a managing director and senior research analyst. He covers over 20 large-, mid-, and small-cap biotechnology stocks. Mr. Schmidt has been recognized in polls conducted by Alpha Magazine, Institutional Investor, Reuters, and The Wall Street Journal. Prior to joining Cowen and Company in 1998 he was a vice president covering the biotechnology sector for UBS Securities. He holds a BA in chemistry from the University of Pennsylvania and a Ph.D. in biochemistry from the Massachusetts Institute of Technology.
Simos Simeonidis
Managing Director
(646) 562-1386
simos.simeonidis@cowen.com
Simos Simeonidis is a managing director and senior research analyst covering the biotechnology sector. Prior to joining Cowen and Company in March 2011, Mr. Simeonidis was a senior research analyst at Rodman & Renshaw and at First Albany Capital and was an associate analyst at Morgan Stanley. Prior to his move to Wall Street he was an associate director in business development/licensing at Novartis and before that he was a faculty member at Harvard Medical School and the Beth Israel Deaconess Medical Center. He holds a BS in biology from Loyola University of Chicago, an MBA in health care management from the Wharton School of the University of Pennsylvania, MA, MPhil, and Ph.D. degrees from Columbia University's College of Physicians and Surgeons, and has completed postdoctoral training at Harvard Medical School and Brigham and Women's Hospital.
Nicholas Bishop
Vice President
(646) 562-1378
nicholas.bishop@cowen.com
Nicholas Bishop is a research analyst covering biotechnology companies. Prior to joining Cowen and Company in July 2010, Mr. Bishop was a postdoctoral fellow at Harvard Medical School studying the genetic causes of cognitive decline during human brain aging. Mr. Bishop received a BA in biochemistry from Rice University and a Ph.D. in biology from MIT.
Kyle Rasbach
Vice President
(617) 946-3925
kyle.rasbach@cowen.com
Prior to joining Cowen and Company in November 2010, Kyle Rasbach was a postdoctoral fellow in the Spiegelman laboratory at Harvard Medical School, where his research focused on the transcriptional regulation of muscle metabolism and related neuromuscular diseases. Mr. Rasbach majored in biology at Denison University, received an MBA from The Citadel, and received Pharm.D. and Ph.D. degrees in pharmaceutical and biomedical sciences from the Medical University of South Carolina.